A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : NSCLC

Search Conditions:
Search Keyword : NSCLC
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: NSCLC
Appearance Frequency: 47446 time(s)
Long forms: 44

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
non-small cell lung cancer
(47313 times)
Neoplasms
(24737 times)
OS (5443 times)
EGFR (5032 times)
PFS (3629 times)
1981 Phase II trial of methylglyoxal-bis-(guanylhydrazone) in non-small-cell lung cancer.
non-SCLC
(58 times)
Neoplasms
(32 times)
SCLC (58 times)
LCNEC (3 times)
OS (3 times)
1986 Paucity of beta 2-microglobulin expression on small cell lung cancer, bronchial carcinoids and certain other neuroendocrine tumors.
non-small cell LC
(12 times)
Neoplasms
(3 times)
LC (11 times)
COPD (2 times)
EMT (2 times)
2006 Trends in the pattern of care for lung cancer and their correlation with new clinical evidence: experiences in a university-affiliated medical center.
non-small-cell bronchial carcinoma
(11 times)
General Surgery
(3 times)
PET (2 times)
ETM (1 time)
FDG (1 time)
1995 [Strategy for staging non-small cell bronchial carcinoma (NSCLC) with special reference to imaging procedures].
Non-Small Cell Lung Cancers
(6 times)
Neoplasms
(4 times)
ALK (2 times)
FISH (2 times)
IHC (2 times)
1995 Loss of heterozygosity at 9p23 defines a novel locus in non-small cell lung cancer.
NSCLC group
(3 times)
Neoplasms
(2 times)
CEA (1 time)
DKK1 (1 time)
ELISA (1 time)
2012 [Expressions and significance of TIMP-3 and mtp53 in non-small cell lung cancer].
early-stagenon-small-cell lung cancer
(2 times)
Neoplasms
(2 times)
AUCs (1 time)
CCRT (1 time)
CGA (1 time)
2018 Multidisciplinary treatment of lung cancer in older patients: A review.
non-small cancer
(2 times)
Allergy and Immunology
(1 time)
KLK6 (1 time)
PAR2 (1 time)
2014 [The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: updated expert recommendations].
non-small cell lung cancer lung cancer
(2 times)
Science
(1 time)
ICB (1 time)
IL-33 (1 time)
RT-qPCR (1 time)
2016 The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update.
10  non-squamous cell lung cancer
(2 times)
Health Services
(1 time)
EGFR-TKIs (1 time)
KM (1 time)
OS (1 time)
2016 Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.
11  progression ofnon-small cell lung cancer
(2 times)
Medicine
(1 time)
circRNAs (1 time)
HBE (1 time)
2016 Inhibiting CREPT reduces the proliferation and migration of non-small cell lung cancer cells by down-regulating cell cycle related protein.
12  abbreviations:Non-small cell lung cancer
(1 time)
Bioengineering
(1 time)
circRNA (1 time)
MSP (1 time)
PTEN (1 time)
2022 Circular RNA hsa_circ_0077837 is upregulated in non-small cell lung cancer to downregulate phosphatase and tensin homolog through methylation.
13  cancer-non-small-cell lung carcinoma
(1 time)
Pulmonary Medicine
(1 time)
--- 2008 CT, positron emission tomography, and MRI in staging lung cancer.
14  inhibitor-naive patients with ALK+non-small cell lung cancer
(1 time)
Medicine
(1 time)
AEs (1 time)
ALK (1 time)
iORR (1 time)
2022 Population pharmacokinetic and exposure-response analyses from ALTA-1L: Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC.
15  lung squamous cell carcinoma
(1 time)
Neoplasms
(1 time)
RCC (1 time)
2016 Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
16  mediastinum foroligometastaticnon-small cell lung cancer
(1 time)
COVID-19 (1 time)
RRP (1 time)
2021 Rapid Development of Clinically Symptomatic Radiation Recall Pneumonitis Immediately Following COVID-19 Vaccination.
17  negatively correlated with the sensitivity to cisplatin
(1 time)
Neoplasms
(1 time)
BRCA1 (1 time)
ERCC1 (1 time)
2008 ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.
18  node positive lung cancer
(1 time)
Thoracic Surgical Procedures
(1 time)
--- 2009 Surgical resection and survival of patients with unsuspected single node positive lung cancer (NSCLC) invading the descending aorta.
19  Non Small Cancer Lung Cells
(1 time)
Cell Biology
(1 time)
--- 2009 Benzo[e]pyridoindoles, novel inhibitors of the aurora kinases.
20  non squamous-cell lung carcinoma
(1 time)
Neoplasms
(1 time)
CEC (1 time)
CEP (1 time)
PR (1 time)
2013 Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.
21  non—small cell lung cancer
(1 time)
Cell Biology
(1 time)
IGF1R (1 time)
2015 MiR-30a suppresses non-small cell lung cancer progression through AKT signaling pathway by targeting IGF1R.
22  non-SCLC tumors
(1 time)
Neoplasms
(1 time)
ExPuSC (1 time)
NE (1 time)
SCLC (1 time)
1992 Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines.
23  non-small cell bronchial cancers
(1 time)
General Surgery
(1 time)
--- 2002 [Neo-adjuvant chemotherapy of non-small cell bronchial cancers (NSCLC)].
24  non-small cell lung cancer, not otherwise specified
(1 time)
Pathology
(1 time)
--- 2000 Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category.
25  non-small cell metastatic lung cancer
(1 time)
Neoplasms
(1 time)
OS (1 time)
PDAC (1 time)
2019 Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy.
26  non-small cell squamous cell carcinoma
(1 time)
--- 2020 Synchronous Multiple Primary Cancers of the Lung: The Rare Association of Non-Small Cell Carcinoma With a Carcinoid Tumor.
27  non-small-cell bronchopulmonary carcinoma
(1 time)
Neoplasms
(1 time)
MDR1 (1 time)
1998 Correlation between multidrug resistance and the degree of differentiation of non-small-cell bronchopulmonary carcinoma (NSCLC) in vitro and in vivo.
28  non-small-cell locally advanced lung cancer
(1 time)
Neoplasms
(1 time)
CR (1 time)
VMAT (1 time)
2012 [Are there any dosimetric advantages in using VMAT for treatment of locally advanced non-small cell lung cancer?].
29  non-small-cell lung cancer therapy
(1 time)
Pharmaceutical Preparations
(1 time)
EGFR (1 time)
2014 Metabolite characterization of anti-cancer agent gefitinib in human hepatocytes.
30  non-small-cell lung cancer, NSCLC
(1 time)
Biochemistry
(1 time)
--- 2011 The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
31  non-smoking lung cancer
(1 time)
Pulmonary Medicine
(1 time)
CI (1 time)
CR (1 time)
OS (1 time)
2006 A phase II study of the docetaxel-carboplatin chemotherapy regimen in advanced non-small-cell lung cancer.
32  nonfermenting (SWI/SNF)Non-small cell lung cancer
(1 time)
Neoplasms
(1 time)
ARID (1 time)
ICIs (1 time)
KM (1 time)
2022 Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.
33  NSC lung cancer
(1 time)
Chemistry, Clinical
(1 time)
EGFR (1 time)
NSC (1 time)
2018 Tissue and Blood Biomarkers in Lung Cancer: A Review.
34  NSCLC cancer
(1 time)
Therapeutics
(1 time)
NRG1 (1 time)
NRG2 (1 time)
2021 NRG1 and NRG2 fusions in non-small cell lung cancer (NSCLC): seven years between lights and shadows.
35  NSCLC cohort
(1 time)
FDA (1 time)
TTD (1 time)
VHA (1 time)
2022 Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation.
36  NSCLC, LUAD and LUSC tissues significantly increased
(1 time)
Neoplasms
(1 time)
FC (1 time)
GEO (1 time)
HOXA3 (1 time)
2018 Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
37  NSCLC-like
(1 time)
SCLC (2 times)
LCNEC (1 time)
2022 Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges.
38  NSCLC-VECs
(1 time)
Cell Biology
(1 time)
MAPK (1 time)
MMP (1 time)
PI3K (1 time)
2022 Luteolin inhibits viability, migration, angiogenesis and invasion of non-small cell lung cancer vascular endothelial cells via miR-133a-3p/purine rich element binding protein B-mediated MAPK and PI3K/Akt signaling pathways.
39  NSCLC/AR
(1 time)
ADAR1 (1 time)
CX3CL1 (1 time)
2021 RNA editing enzyme adenosine deaminases acting on RNA 1 deficiency increases the sensitivity of non-small cell lung cancer cells to anlotinib by regulating CX3CR1-fractalkine expression.
40  numerous algerian patients with bronchopulmonary cancers cells
(1 time)
Biology
(1 time)
--- 2019 [In silico study of a functional mutation associated with non-small cell lung cancer: G12D mutation of exon 2 in KRAS gene].
41  patients withnon-small cell lung cancer
(1 time)
Neoplasms
(1 time)
EVs (1 time)
ICIs (1 time)
2022 Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer.
42  pneumonectomy fornon-small cell lung cancer
(1 time)
General Surgery
(1 time)
GPS (1 time)
ICU (1 time)
2016 Glasgow Prognostic Score Class 2 Predicts Prolonged Intensive Care Unit Stay in Patients Undergoing Pneumonectomy.
43  predominantly sarcomas,non-small cell lung cancer
(1 time)
NTRK (1 time)
2022 The First Reported Case of Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Thymoma Treated Successfully With Entrectinib.
44  recombination', 'non-small cell lung cancer
(1 time)
Neoplasms
(1 time)
CI (1 time)
HJURP (1 time)
HR (1 time)
2022 Prognostic value of Holliday junction-recognizing protein and its correlation with immune infiltrates in lung adenocarcinoma.